Checked
Zai Lab Ltd
Nasdaq: ZLAB · Pharmaceutical Preparations · Shanghai, China
- Revenue
- $460.2M
- +15.3% vs. prior year
- Net income
- -$175.5M
- -38.1% net margin
- Total assets
- $1.17B
- Diluted EPS
- -$0.16
Company details
As reported to the SEC
- SEC CIK
- 1704292
- Stock
- Nasdaq: ZLAB
- Legal Entity Identifier (LEI)
- 549300P2UYQ9U5LY1T58
- Industry (SIC)
- Pharmaceutical Preparations (2834)
- Headquarters
- Shanghai, China
- Fiscal year end (SEC record)
- December 31
- Filer status
- Large accelerated filer
- Last annual report
- 02/26/2026
- Last quarterly report
- 08/06/2026
Annual financials
U.S. dollars, as tagged in each annual report's XBRL data. Later restatements replace earlier numbers. Select a date to open the filing.
| Fiscal year ended | 12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 |
|---|---|---|---|---|---|
| Revenue | $460.2M | $399M | $266.7M | $215M | $144.3M |
| Operating income | -$229.4M | -$282.1M | -$366.6M | -$404.4M | -$700.1M |
| Net income | -$175.5M | -$257.1M | -$334.6M | -$443.3M | -$704.5M |
| Diluted earnings per share | -$0.16 | -$0.26 | -$0.35 | -$0.46 | -$0.76 |
| Research and development | $220.9M | $234.5M | $265.9M | $286.4M | $573.3M |
| Total assets | $1.17B | $1.19B | $1.04B | $1.22B | $1.61B |
| Total liabilities | $456.9M | $344.9M | $240.2M | $174.5M | $230M |
| Shareholders' equity | $715.5M | $840.9M | $796.1M | $1.05B | $1.38B |
| Cash and cash equivalents | $679.6M | $449.7M | $790.2M | $1.01B | $964.1M |
| Cash from operations | -$150.8M | -$214.9M | -$198.2M | -$367.6M | -$549.2M |
| Capital expenditures | $8.1M | $5.66M | $7.21M | $24.59M | $18.3M |
Subsidiaries
17 companies that Zai Lab Ltd owns or controls, as listed in its SEC annual report (Exhibit 21), GLEIF ownership records or USAspending
| Subsidiary | Listed in |
|---|---|
| ZL Capital Limited | SEC 10-K |
| ZL China Holding Two Limited | SEC 10-K |
| ZLIP Holding Limited | SEC 10-K |
| Zai Anti Infectives (Hong Kong) Limited | SEC 10-K |
| Zai Anti Infectives Limited | SEC 10-K |
| Zai Auto Immune (Hong Kong) Limited | SEC 10-K |
| Zai Auto Immune Limited | SEC 10-K |
| Zai Biopharmaceutical (Suzhou) Co., Ltd | SEC 10-K |
| Zai Lab (AUST) Pty. Ltd. | SEC 10-K |
| Zai Lab (Hong Kong) Limited | SEC 10-K |
| Zai Lab (Shanghai) Co., Ltd. | SEC 10-K |
| Zai Lab (Suzhou) Co., Ltd. | SEC 10-K |
| Zai Lab (Taiwan) Limited | SEC 10-K |
| Zai Lab (US) LLC | SEC 10-K |
| Zai Lab (Zhejiang) Co., Ltd. | SEC 10-K |
| Zai Lab International Trading (Shanghai) Co., Ltd. | SEC 10-K |
| Zai Lab Trading (Suzhou) Co., Ltd. | SEC 10-K |
Recent filings
60 recent filings on record; insider ownership forms (3, 4, 5 and 144) are not listed here
Swipe the table sideways to see more columns.
92 insider ownership reports (Forms 3, 4, 5 and 144) were filed about Zai Lab Ltd in the last 12 months. They list trades by officers, directors and large holders; see them on SEC EDGAR.
Other pharmaceutical preparations
Swipe the table sideways to see more columns.
| Company | Headquarters | Revenue | Net income |
|---|---|---|---|
| Johnson & JohnsonJNJ | New Brunswick, NJ | $94.19B | $26.8B |
| Eli Lilly & CoLLY | Indianapolis, IN | $65.18B | $20.64B |
| Merck & Co., Inc.MRK | Rahway, NJ | $65.01B | $18.25B |
| Pfizer IncPFE | New York, NY | $62.58B | $7.77B |
| AbbVie Inc.ABBV | North Chicago, IL | $61.16B | $4.23B |
| Astrazeneca PLCAZN | Cambridge, United Kingdom | $58.74B | $10.22B |
| Bristol Myers Squibb CoBMY | Princeton, NJ | $48.19B | $7.05B |
| Abbott LaboratoriesABT | Abbott Park, IL | $44.33B | $6.52B |
Profile refreshed Oct 26, 2026; financials refreshed Oct 22, 2026.
Frequently asked questions
- What is Zai Lab Ltd's CIK number?
- Zai Lab Ltd's SEC Central Index Key (CIK) is 1704292.
- What is Zai Lab Ltd's stock ticker?
- Zai Lab Ltd trades as Nasdaq: ZLAB.
- What was Zai Lab Ltd's revenue?
- Zai Lab Ltd reported revenue of $460.2M for the fiscal year ended Dec 31, 2025, +15.3% from the year before.
- When does Zai Lab Ltd's fiscal year end?
- Zai Lab Ltd's fiscal year end on file with the SEC is December 31; its most recent fiscal year ended Dec 31, 2025.
- Where is Zai Lab Ltd headquartered?
- Zai Lab Ltd's principal executive office on file with the SEC is in Shanghai, China.
- What companies does Zai Lab Ltd own?
- Zai Lab Ltd lists 17 subsidiaries in its SEC filings and other public records, including ZL Capital Limited, ZL China Holding Two Limited, ZLIP Holding Limited.
Source: U.S. Securities and Exchange Commission, EDGAR submissions and XBRL company facts · Last updated 10/26/2026